Please assess the completion status of the following clinical trial:

Trial Title: Febuxostat Versus Allopurinol Control Trial in Subjects With Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meeting the preliminary criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout.~* Serum uric acid ≥ 8.0 milligrams per deciliter (mg/dL) at Baseline~Exclusion Criteria:~* Serum creatinine \>1.5 mg/dL~* Calculated creatinine clearance of \<50 milliliters per minutes (mL/min)~* Pregnancy or lactation;~* Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine, thiazide diuretics, or medications containing aspirin (\>325 mg) or other salicylates;~* Body Mass Index (BMI) \>50 kilogram per meter²(kg/m²);~* A history of xanthinuria, active liver disease, or hepatic dysfunction;~* A history of alcohol abuse or intake of 14 or more alcohol-containing drinks/week.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 120 mg QD (Type: EXPERIMENTAL): None
- Allopurinol 300 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).